24 Jan

XXVIII Congrés de la Societat Catalana de Digestologia

XXVIII Congrés de la Societat Catalana de Digestologia

L’equip científic de GoodGut presentarà quatre pòsters al XXVIII Congrés de la Societat Catalana de Digestologia, que se celebrarà del 24 al 26 de gener al Palau Firal i de Congressos de Tarragona:

  • L’ús d’una nova signatura bacteriana fecal per a la personalització del seguiment del síndrome de Lynch a càrrec de Marta Malagón
  • Compensació de l’activitat enzimàtica de pacients amb pancreatitis crònica per la microbiota intestinal a càrrec de Lia Oliver
  • RAID-Dx: El primer test per al diagnòstic de la Síndrome de l’Intestí Irritable basat en la microbiota fecal a càrrec de Joan Amoedo
  • Estudi de l’efecte de la dieta en la microbiota intestinal en participants del programa de cribratge del càncer colorectal a càrrec de Marta Malagón

Data: del 24 al 26 de gener de 2019
Lloc: Palau de Congressos de Tarragona

Més informació

 

24 Jan

Interclúster “Nutrició i salut: descobrint nous reptes”

Interclúster “Nutrició i salut: descobrint nous reptes”

GoodGut participarà a l’Interclúster Nutrició i salut: descobrint nous reptes que organitzen CataloniaBio & HealthTech, el Clúster de Salut Mental i el Food Nutrition Cluster, el dia 24 de febrer a Sant Boi de Llobregat, amb l’objectiu de debatre les necessitats no cobertes al sector i poder aportar el seu coneixement com a empresa dedicada a la recerca i desenvolupament de sistemes no invasius de suport al diagnòstic i al tractament de malalties digestives basats en la microbiota intestinal.

Data: 24 de febrer de 2019
Lloc: Palau Marianao · Passeig President Josep Terradellas, 25 · Sant Boi de Llobregat

Més informació

06 Dec

Mariona Serra receives the Fidem award for innovation

Mariona Serra receives the Fidem award for innovation

The co-founder and CEO of GoodGut, Mariona Serra, was honoured with the Fidem 2018 award for innovation at a gala held on 29 November in CaixaFòrum Barcelona. Serra received the award from the Catalan Minister of the Presidency, Elsa Artadi, who took part in the event alongside the Minister of Enterprise and Knowledge, Àngels Chacón.

For the last 21 years, the International Foundation for Women Entrepreneurs (Fidem) has through this award recognised successes and initiatives by women who, through good management of their businesses, contribute to economic and social development. “These women are pioneers in their speciality and will become a reference for future generations” explained Joana Amat, president of Fidem.

“I was delighted to receive this recognition as women are well represented within GoodGut, not only in management but also the scientific team. It was a very exciting award. It is important to continue to raise the profile of women in the world of business and entrepreneurship” said Mariona Serra.

Fidem also recognised the talent of seven other businesswomen, entrepreneurs and executives: Therese Jamaa, General Manager of GSMA Mobile World Capital; Angie Rosales, director of Pallapupas; Inka Guixà, Chief Executive of La Farga; Àngels Roqueta, founding partner of Compas Private Equity; Aina Juliol, CEO of PGI Engineering; Emília Vila, co-founder and CEO of Agroptima, and Mireia Banega, founder of Eya Bach.

News in the press:

 

05 Dec

Biocat Report 2017 Presentation

Biocat Report 2017 Presentation

GoodGut will participate at the presentation of the Biocat Report 2017, the reference study that analyzes the life sciences and healthcare sector in Catalonia, on 5th December in Barcelona.

The event will be chaired by The Honorable Quim Torra, President of the Generalitat de Catalunya, and Mr. Jordi Naval, CEO of Biocat.

The meeting will include the keynote by Dr. Daria Tataj, chairwoman of the RISE High-Level Advisors to Carlos Moedas, European Commissioner for Research, Science and Innovation, and success stories of technology transfer in Catalonia:

Date: 5 December, 2018
Place: Auditorium Axa · Avinguda Diagonal, 547 · Barcelona

More information

Check the reference study of the BioRegion of Catalonia, a publication summarizing the situation and trends of the sector.

12 Nov

Oncothon 2018

Oncothon 2018

In the framework of the Onconet Sudoe European project, Oncothon will be a 2-day event that will bring the opportunity for professional from different areas such as oncology, bioinformatics, engineer or biomedical research, from academic and enterprise settings, to know how cancer genomics is opening new pathways for cancer diagnosis and treatment.

Attendees will have the opportunity to attend outstanding talks about how to exploit cancer genomics data and participate in collaborative sessions with interdisciplinary teams to collaborate and brainstorm about innovative solutions.

The institutional opening will be in charge of Angela Moca, Onconet Sudoe project coordinator (Université Toulouse III Paul Sabatier) and Lina Gálvez, regional minister of Knowledge, Research and University of Junta de Andalucía.

Goodgut has invited at the Cancer Interception Workshop on 12 November. Sara Ramió, Project Manager at GoodGut, will talk about The Microbiome and Cancer with Eduardo Pareja of Era7 Bioinformatics. GoodGut is developing RAID-CRC, a pioneering test non-invasive, fast, easy to use and economical to pre-diagnose colon cancer and determine the risk in previous stages, using biomarkers in stool samples.

This Oncothon arises in the framework of the Onconet Sudoe European project.

Date: 12-13 November, 2018
Place: Parque Tecnológico de Ciencias de la Salud de Granada

More information

 

26 Oct

Gebro Pharma and Goodgut unite to advance the treatment of Crohn’s disease

Gebro Pharma and Goodgut unite to advance the treatment of Crohn’s disease

Gebro Pharma and Goodgut have come together to explore, by means of a clinical trial, whether or not variations in the composition of intestinal flora influence patients’ response to treatment for inflammatory bowel disease (IBD) in order to define these bacterial markers as a parameter for predicting which patients will respond best.

It is estimated that IBD currently affects around 2.2 million people in Europe and approximately 120,000 in Spain, with the incidence of the disease rising globally. The existing treatments not only have a high cost and significant side effects, but are effective in only 60% of patients, of whom around 50% end up becoming non-responsive to the treatment.

Recent studies indicate that the bacterial communities present in the colon mucosa of a patient with Crohn’s disease, ulcerative colitis or irritable bowel syndrome (IBS) are structurally different from those of healthy individuals.

The University Hospital Doctor Josep Trueta in Girona is participating in the trial, led by Dr Xavier Aldeguer, Head of the Digestive Tract Department at the hospital, and Lecturer in Digestive Physiology at the University of Girona Faculty of Medicine. Other team members include Mariona Serra, Goodgut CEO and pharmacologist, and Bellvitge University Hospital, with the collaboration of Dr Jordi Guardiola, Head of its Digestive Tract Department.

The growing role of intestinal microbiota

In recent years the role of microbiota has gradually become clearer, and studies on the matter have become increasingly common due to the relevance and impact that resident bacteria in physiology and pathology have on human health.

The main functions of intestinal microbiota include metabolic activities, that is, the recovery of energy and nutrients, and protection of the individual against invasion by foreign micro-organisms. Intestinal bacteria also play an essential role in developing and modulating the immune system, meaning that alterations to the balance of these bacterial species have significant repercussions involving microflora in multiple pathological processes, not only in the gastrointestinal tract, as in IBD or colon cancer, but in the whole organism.

With bacterial flora having been described as an agent triggering the pathogenesis of IBD, the effectiveness of the treatment of said diseases could be subject to differences in its composition. In fact, around 30% of the patients do not respond to treatment have intestinal dysbiosis (imbalance or impoverishment); it appears that this factor means that a higher degree of dysbiosis means a lower response to the treatment.

26 Oct

Jornada científica – 5º Aniversario del Biobanco IDIBGI

Jornada científica – 5º Aniversario del Biobanco IDIBGI

El Biobanco IDIBGI celebrará una jornada científica con motivo de su quinto aniversario, el día 26 de octubre en el Hospital Santa Caterina de Salt (Girona), en la cual se abordarán temas como los nuevos retos de la Red Nacional de Biobancos, biobancos e investigación clínica, utilidad y diversidad de los biobancos.

La inauguración de la jornada irá a cargo de Jordi Barretina, director del Instituto de Investigación Biomédica de Girona Dr. Josep Trueta (IDIBGI), y José Manuel Fernández-Real, director del Biobanco IDIBGI.

Sara Ramió, Project Manager de GoodGut, impartirá la charla GoodGut, ejemplo de colaboración público-privada.

En la clausura participarán Luis Gallart, coordinador del Biobanco IDIBGI, y Albert Barberà, director general de Investigación e Innovación en Salud de la Generalitat de Catalunya.

Fecha: 26 de octubre de 2018
Lugar: Hospital Santa Caterina · C/ Dr. Castany, s/n (Parc Hospitalari Martí i Julià – Edifici 1) · Salt (Girona)

Consulta el programa

Inscríbete

25 Oct

Workshop Palex Medical sobre enfermedad inflamatoria intestinal

Workshop Palex Medical sobre enfermedad inflamatoria intestinal

Palex Medical celebrará el workshop Nuevas perspectivas en el laboratorio para el diagnóstico diferencial y monitorización de enfermedad inflamatoria intestinal (EII), el día 25 de octubre en Bilbao, con los doctores Xavier Aldeguer, jefe del Servicio Aparato Digestivo del Hospital Universitario Doctor Josep Trueta y director médico de GoodGut; la Dra. Lorena Rodríguez, especialista del Servicio Aparato Digestivo del Hospital Universitario de Bellvitge, y la Dra. Rocío Ferreiro-Iglesias, especialista en EII del Servicio Aparato Digestivo del Complejo Universitato de Santiago de Compostela. El moderador será el Dr. Antonio Buño, jefe del Servicio Análisis Clínicos del Hospital Universitario La Paz.

Concretamente, el Dr. Aldeguer explicará la microbiota intestinal como un nuevo marcador clave para el diagnóstico diferencial y seguimiento del síndrome de intestino irritable y la EII.

Fecha: 25 de octubre de 2018
Lugar: Labclin · Bilbao

20 Oct

26th United European Gastroenterology Week

26th United European Gastroenterology Week

The 26th United European Gastroenterology Week (UEG Week), the largest and most prestigious meeting of its kind in Europe, will be held in Vienna from 20 to 24 October 2018. UEG Week has been running since 1992, in a variety of major cities, and now attracts up to 16,000 people from 111 countries. Five intensive days of scientific advances, updates and getting together of practitioners, top scientists and everyone invested in digestive health.

Dr Antoni Castells, Medical Director of the Hospital Clínic, co-coordinator of the Barcelona’s Colorectal Cancer Screening Program and Medical Advisor of GoodGut, will present the RAID-CRC non-invasive test in the “Best of UEG”.

GoodGut team will be at the poster sessions:

  • RAID-CRC: A novel non-invasive tool for colorectal cancer screening based on bacterial signatures capable of reducing the faecal immunochemical test false-positive. Marta Malagón, Spain; Ramió-Pujol S.; Serrano M.; Serra-Pagès M.; Amoedo J.; Oliver L.; Bahí A.; Mas-de-Xaxars T.; Torrealba L.; Gilabert P.; Miquel-Cusachs O.; García-Nimo L.; Saló J.; Guardiola J.; Piñol V.; Cubiella J.; Castells A.; Aldeguer X.; Garcia-Gil J.
  • RAID-LS: A non-invasive tool based on a faecal bacterial signature for Lynch syndrome surveillance. Marta Malagón, Spain; Ramió-Pujol S.; Serrano M.; Serra-Pagès M.; Amoedo J.; Oliver L.; Bahí A.; Guardiola J.; Navarro M.; Piñol V.; Pineda M.; Capellà G.; Castells A.; Garcia-Gil J.; Aldeguer X.; Brunet J.

Date: 20-24 October, 2018
Place: Vienna (Austria)

More information

17 Oct

Healthio 2018

Healthio 2018

GoodGut is to present its non-invasive tests to support the diagnosis and treatment of digestive diseases using intestinal microbiota as a determinant factor at Healthio 2018, the event focused on the latest technological solutions in healthcare, during Barcelona Industry Week. GoodGut has been invited to speak at the Innovation Café organised by the Centre for the Integration of Medicine and Innovative Technologies (CIMTI).

Healthio 2018 will bring together users, professionals, entrepreneurs and innovators from within the health service (wellness, personalised medicine of the future, chronic illnesses and ageing). It will host 115 exhibiting companies, with 310 presentations by patients and experts.

CIMTI InnovationCafé
Date: 17 October, 2018 (BOOTH B200)
Time: 14:30 pm
Place: Fira Barcelona · Montjuïc Venue (Hall 8) · Av. Maria Cristina, s/n

Sign up (Professional visitor code 67C56DA0)